Wuhan YZY Biopharma Co Ltd
02496
Company Profile
Business description
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.
Contact
No. 666 Gaoxin Road
East Lake High Tech
Development Zone
Hubei Province
Wuhan
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
114
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,704.40 | 143.20 | -1.82% |
| CAC 40 | 7,100.42 | 173.30 | 2.50% |
| DAX 40 | 20,280.26 | 490.64 | 2.48% |
| Dow JONES (US) | 38,859.49 | 1,686.44 | -4.16% |
| FTSE 100 | 7,910.53 | 144.45 | -1.79% |
| HKSE | 20,127.68 | 2,722.13 | -11.91% |
| NASDAQ | 15,971.30 | 579.30 | -3.50% |
| Nikkei 225 | 33,012.58 | 768.00 | -2.27% |
| NZX 50 Index | 11,891.44 | 333.84 | -2.73% |
| S&P 500 | 5,174.92 | 112.67 | 2.23% |
| S&P/ASX 200 | 7,510.00 | 157.80 | -2.06% |
| SSE Composite Index | 3,145.55 | 48.97 | 1.58% |